Archive of ‘TMS’ category

Combining TMS with Psychotherapy for Treating Depression and OCD

Transcranial Magnetic Stimulation (TMS), a safe, non-invasive type of brain stimulation, was approved by the FDA for the treatment of depression in 2008, and is now clinically available for the treatment of adults who have not been helped by antidepressant medications. Recently, FDA cleared TMS for use in patients with obsessive-compulsive disorder, if given immediately […] Read more…

Neuromodulation for treatment-resistant depression

Abstract Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical stimulation, and deep brain stimulation among others. […] Read more…

The expanding evidence base for rTMS treatment of depression

Mark S. George, Joseph J. Taylor, and E. Baron Shor INTRODUCTION Transcranial magnetic stimulation (TMS) is perhaps the most popular of the new brain stimulation techniques because its clinical effects are produced without the need for a craniotomy [as with deep brain stimulation (DBS)] or seizure induction [as with electroconvulsive therapy (ECT)]. As a focal, […] Read more…

Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States

Abstract INTRODUCTION: Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. Transcranial magnetic stimulation (TMS) is a US Food and Drug Administration-approved treatment for major depressive disorder (MDD) in patients who have not responded to […] Read more…

‘Deep’ TMS Beats Standard TMS, Meds for Severe Depression

Author: Batya Swift Yasgur, MA, LSW Date: July 31, 2019 “Deep” repetitive transcranial magnetic stimulation (rTMS) plus standard antidepressant medication is significantly more effective at reducing depression levels in patients with major depressive disorder (MDD) than standard rTMS or stand-alone pharmacotherapy, new research suggests. In a randomized study, almost 230 participants with treatment-resistant depression (TRD) received either […] Read more…

Innovative Solutions That Spark Renewal & Relief

In the medical field, 175 years is a long time.  It probably goes without saying that there have been some major advancements in medicine over the passing decades. Medicines and treatments that brought innovative care, a deeper understanding, and relief for those suffering from common mental illnesses. For these reasons (and more!), we celebrate the […] Read more…

Efficacy of repetitive transcranial magnetic stimulation using a figure-8-coil or an H1-Coil in treatment of major depressive disorder; A randomized clinical trial

Remission rate was significantly greater in HF-rTMS groups compared to the control. Main-analyses showed no difference in remission rate between H1-coil, and 8-coil group. Better response rate and reduction of depression severity was observed in H1-coil, then in 8-coil group, although H1-coil protocol uses a smaller number of pulses and has a shorter duration of […] Read more…

new depression treatments nyc 2019

3 Exciting Developments In Mental Health Care

2019 is off to a great start! New research and developments in psychiatric care help pave the way to enhanced treatment options for common mental illnesses. These advancements offer life-changing possibilities to those who need something more than standard protocol. Here’s a quick recap… Esketamine’s FDA Approval The FDA’s approval of esketamine (Spravato) nasal spray […] Read more…

Spotlight on Esketamine & Interventional Psychiatry

How do you help someone lost in darkness of deep depression? The loneliness, the emptiness-the hopelessness?             In the field of psychiatry, our first-line treatment usually consists of psychotherapy and medication. Most patients receive benefits and maintain improvement from these treatments. But, for the one-third of patients who are failed by traditional protocol, interventional psychiatry […] Read more…

Three Take-Away’s from the 2019 CTMS Conference to Keep an Eye On

The 2019 CTMS Conference in Vancouver BC was chalk-full of exciting conversations and take-away’s. Amanda Itzkoff, MD of NYC Psychiatry was excited to participate. Here are three exciting developments you may want to keep tabs on in the future: Combination of Ketamine & TMS as a Treatment for TRD There have been rumblings about using […] Read more…

1 2